drugset / Trial / NCT00003479

Antineoplaston Therapy in Treating Patients With Ependymoma

NCT00003479

Phase 2 Terminated 9 enrolled Burzynski Research Institute
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Current therapies for patients with ependymoma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of patients with ependymoma . PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with ependymoma.

Timeline

Start
1966-07
Primary completion
2000-10
Completion
2000-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Astugenal Unknown Intravenous
Subject antineoplaston A10 Small molecule Intravenous

Indications